Meeting
2019 Gastrointestinal Cancers Symposium
A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
Authors
Manish A. Shah
Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
Manish A. Shah , Jean-Philippe Metges , David Cunningham , Kai-Keen Shiu , Lucjan Wyrwicz , Dung Thai , Carrie Brachmann , Pankaj Bhargava , Daniel V.T. Catenacci , Zev A. Wainberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02864381
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 75)
DOI
10.1200/JCO.2019.37.4_suppl.75
Abstract #
75
Poster Bd #
H5
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
First Author: Manish A. Shah
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study.
First Author: Tingbo Liang
